Zhang Li, Zou Yao, Ai Xiao-Fei, Cao Zeng, Chen Yu-Mei, Guo Ye, Yang Wen-Yu, Chen Xiao-Juan, Wang Shu-Chun, Liu Xiao-Ming, Ruan Min, Liu Tian-Feng, Liu Fang, Qi Ben-Quan, Chang Li-Xian, An Wen-Bin, Ren Yuan-Yuan, Li Qing-Hua, Zhu Xiao-Fan
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020 Dec;28(6):1831-1836. doi: 10.19746/j.cnki.issn.1009-2137.2020.06.007.
To investigate the consistency between FCM and PCR on the detecting of MRD in TCF3-PBX1 ALL, and to investigate the prognosis value of these 2 methods.
55 cases of paediatric TCF3-PBX1 ALL patients from April 2008 to April 2015 were enrolled and analyzed. The FCM and PCR was used to detect the MRD in 239 bone marrow samples of 55 patients. All statistical analyses were carried out by using SPSS software version 16.
Among the 55 children with TCF3-PBX1 ALL, there were 30 male and 25 female. The median age was 5 (1-14) years. 20 patients relapsed during follow-up. The MRD results from PCR and FCM showed a strong correlation between both methods (K=0.774, P<0.001). There was no significant difference in 5-years DFS and OS between the patients in PCR and PCR groups on day 15 or day 33. The 5 year DFS rate between the patients in FCM and FCM was 63.9%±7.0% and 0; the 5 year OS rate was 66.5%±7.9% and 0. Combined with the result of FCM and PCR, at the d 33 of treatment, the 5-year DFS rate in FCM/PCR and single positive group was 65.4%±7.2% and 25.0%±15.3% (P<0.01).
The detection result of MRD in TCF3-PBX1 detect by FCM and PCR shows better consistency. MRD positivity detected by FCM at the end of induction therapy (day 33) predicts a high risk of relapse in TCF3-PBX1 ALL patients.
探讨荧光定量聚合酶链反应（PCR）与流式细胞术（FCM）检测TCF3-PBX1急性淋巴细胞白血病（ALL）微小残留病（MRD）的一致性，并研究这两种方法的预后价值。
纳入2008年4月至2015年4月间55例儿童TCF3-PBX1 ALL患者进行分析。采用FCM和PCR检测55例患者239份骨髓样本中的MRD。所有统计分析均使用SPSS 16.0软件进行。
55例TCF3-PBX1 ALL患儿中，男30例，女25例。中位年龄为5（1-14）岁。20例患者在随访期间复发。PCR和FCM检测MRD的结果显示两种方法之间具有很强的相关性（K=0.774，P<0.001）。在第15天或第33天，PCR组和PCR组患者的5年无病生存率（DFS）和总生存率（OS）无显著差异。FCM组和FCM组患者的5年DFS率分别为63.9%±7.0%和0；5年OS率分别为66.5%±7.9%和0。结合FCM和PCR结果，在治疗第33天，FCM/PCR双阳性组和单阳性组的5年DFS率分别为65.4%±7.2%和25.0%±15.3%（P<0.01）。
FCM和PCR检测TCF3-PBX1中MRD的结果显示出较好的一致性。诱导治疗结束时（第33天）通过FCM检测到的MRD阳性预示着TCF3-PBX1 ALL患者有较高的复发风险。
